Showing results (391-400 of 517) with videos related to

Sort By:
Pageof 52
Physical Review Letters|April 28, 2009
Transverse acoustic excitations in liquid GaS Hosokawa, M Inui, Y Kajihara, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 25, 2014
99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen: pharmacokinetics and biodistribution studies in healthy subjects and patients with metastatic prostate cancerShankar Vallabhajosula, Anastasia Nikolopoulou, John W Babich, et al.
Journal of Physics. Condensed Matter : an Institute of Physics Journal|August 26, 2021
Low energy excitation in liquid Sb and liquid Bi observed in inelastic x-ray scattering spectraM Inui, Y Kajihara, S Hosokawa, et al.
Journal of the American Academy of Dermatology|November 1, 1992
The effect of intralesional 5-fluorouracil therapeutic implant (MPI 5003) for treatment of basal cell carcinomaE K Orenberg, B H Miller, H T Greenway, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 30, 2013
Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancerScott T Tagawa, Matthew I Milowsky, Michael Morris, et al.
European Urology|February 8, 2016
Phase 1b Study of Abiraterone Acetate Plus Prednisone and Docetaxel in Patients with Metastatic Castration-resistant Prostate CancerScott T Tagawa, Edwin M Posadas, Justine Bruce, et al.
Neoplasia (New York, N.Y.)|January 30, 2013
Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancerJuan Miguel Mosquera, Himisha Beltran, Kyung Park, et al.
Neurology|May 30, 2002
Long-term response to zonisamide in patients with West syndromeY Suzuki, K Imai, Y Toribe, et al.
Nature Genetics|November 8, 2016
Clonal evolution of chemotherapy-resistant urothelial carcinomaBishoy M Faltas, Davide Prandi, Scott T Tagawa, et al.
European Urology|September 6, 2024
Association of Declining Prostate-specific Antigen Levels with Clinical Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Receiving [177Lu]Lu-PSMA-617 in the Phase 3 VISION TrialAndrew J Armstrong, Oliver Sartor, Johann de Bono, et al.
Pageof 52